Aid in dying wins approval if patient gives lethal dose

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 1
Volume 18
Issue 1

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

In 2008, Washington state passed an initiative that allows doctors to prescribe lethal prescriptions to terminally ill patients who have six months or less to live. The physician must also recommend, but not require, the patient to notify next of kin. The initiative is similar to Oregon’s 1998 Death With Dignity Act.

Of those who responded to the December poll question (“Do you agree with physician-assisted suicide?”), 24% said yes, if physicians determine survival time is less than six months.

Another 24% said yes, if the patient self administers the lethal dose of medication. Finally, 16% voted in favor of having the physician administer the lethal dose.

On the other hand, 16% said no because physician-assisted suicide validates euthanasia while another 16% voted no, not under any circumstances.

See page 2 and visit www.cancernetwork.com to register your vote on this month’s question, “Considering what we know now, should ESAs ever have been approved for chemotherapy-induced anemia?”

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content